Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
101 Cards in this Set
- Front
- Back
- 3rd side (hint)
Describe Dietary Reference Intakes (DRIs)
|
Are established for gender, life‐stage, & conditions
(ex: pregnancy, lactation). - They reflect average need per day over a period of time *deviation from the average is expected.* - Are set for healthy people – currently does not account for acute/chronic disease or repletion of a deficiency or malnutrition. |
|
|
EAR |
average daily nutrient intake level estimated to meet the requirement of 50% of individuals in a group.
|
|
|
RDA
|
level sufficient to meet the requirement of nearly all (97‐98%) individuals in a group.
EAR & RDA reference values based on estimates of nutrient requirements vary among individuals – assumed to approximate a normal distribution. The median of the distribution = estimated average requirement or the EAR. The RDA is set two standard deviations above the median. |
|
|
Adequate Intake (AI) |
Nutrient level based on observed or experimentally determined approximation of nutrient intake by a group of healthy people when sufficient scientific evidence is not available to calculate RDA. |
|
|
Tolerable Upper Intake Level (UL) |
- Highest daily nutrient intake level that is likely to pose no risk from adverse effects to most individuals in the general population.
- As intake increase above UL, risk from adverse effects increases. Applies to chronic use – may be based on total intake |
|
|
Factors influencing bioavailability |
Diet‐related – Food matrix or structure (bound to components in food) – Chemical form of nutrient (heme vs non heme iron) – Interactions among nutrients – Interactions with food compounds (inhibitors/enhancers) – Processing/treatment of food
Host‐related: – Intestinal factors – Age – Physiologic state |
|
|
Phytates |
- storage form of phosphate in certain plant‐based foods (unrefined cereals, legumes,nuts & seeds). - In the gastrointestinal tract, phytates bind with certain minerals –> iron, zinc, calcium, and magnesium forming insoluble complexes. |
|
|
Polyphenols |
Found in most plants –– Involved in pigmentation, growth, and protection from consumption – Sources: lentils, kidney beans, spinach, oregano, tea, coffee, red wine, and cocoa. - Polyphenols can interfere with intestinal absorption of nutrients, particularly minerals‐ ex: complexes with nonheme iron. |
|
|
Heme Iron |
- Found in meats, poultry, fish. Derived from hemoglobin and myoglobin.
- Better absorbed than non-heme iron. - Heme Fe must be hydrolyzed from the globin portion of |
|
|
Heme Iron absorption |
Heme Fe is soluble and is readily absorbed intact through the duodenum by a putative apical membrane heme receptor HCP1 = heme carrier protein 1 HRG1 = heme responsive gene-1 Within the enterocyte Heme oxygenase (HO) can release Fe from heme so it can join the non heme iron and be stored or utilized. Alternatively, intact heme may be released across the basolateral surface via the heme exporter FLVCR1 (Feline leukemia virus, type C, receptor 1)
|
|
|
Non-heme iron |
Uptake of nonheme Fe by enterocytes is better understood – Although less effectively absorbed, nonheme Fe is present in a greater range of foods, most typically in the ferric iron (Fe+3) form – HCl, pepsin & other proteases release Fe from food most Fe is present as ferric iron (Fe+3) in the stomach – Non-heme Fe must be freed and reduced in the GI tract for absorption to occur |
|
|
Regulation of Iron absorption |
Fe balance controlled at point of absorption
– Absorption is closely tied to the level of the body’s Fe stores – Absorption is normally low.....~10% with normal Fe status – Absorption is increased (~35%) during Fe deficiency |
|
|
DMT1 |
Divalent metal transporter 1 (DMT1)
– Transport protein located on the apical membrane – Transports Fe+2 across the apical membrane |
|
|
Dcytb |
Duodenal Cytochrome B - Located on the apical membrane of the enterocyte
– Dcytb reduces Fe+3 to Fe+2 |
|
|
Once Fe2+ has been absorbed into the enterocyte it can follow one of these three paths |
1. The iron can be utilized by the intestinal cell as needed.
2. The iron could be stored in the cell as ferritin. Ferritin uses its feroxidase to convert the ferrous iron back into ferric iron.
3. It can be exported from the intestinal cell through the ferroportin transporter that sits on the basolateral membrane. |
|
|
Ferritin |
Ft stores Fe. Ferritin contains a ferroxidase that convert Fe2+ to
Fe3+ for deposition & storage within its core. The stored Fe (Fe3+) can be reduced back to Fe2+ & released by Ft if needed by the mucosal or other non-intestinal cells. If not needed, the Fe remains within the Ft molecule and is excreted when the mucosal cells are sloughed off (2-3 d) – Ferritin synthesis in the intestine is directly affected by Fe status (positive.....more Fe = more Ft) |
|
|
Ferroportin |
a transmembrane protein that transports iron from the inside of a cell to the outside of the cell.
– transports Fe2+ across the basolateral membrane |
|
|
Hephaestin |
a transmembrane copper-dependent ferroxidase necessary for effective iron transport from intestinal enterocytes into the circulation.
Oxidizes the Fe from ferrous form (Fe2+) to ferric iron (Fe3+) |
|
|
How does copper deficiency affect iron status? |
Cu deficiency results in the accumulation of Fe in intestine & liver
|
|
|
Transferrin |
Once across the basolateral membrane, transferrin transports Fe+3 in circulation. Tf transports iron through the blood to various tissues, such as the liver, spleen, and bone marrow. Requires oxidation by Hephaestin (cell membrane) and
ceruloplasmin (intracellular): Both Cu-containing proteins with ferroxidase activity |
|
|
Transferrin Recepter & TfR cycle |
Transferrin receptor (TfR) is a carrier protein for transferrin. - It is needed for the import of iron into cells and is regulated in response to intracellular iron concentration. - Iron uptake depends on the transferrin saturation level. - For uptake to occur, transferrin binds to the transferrin receptor (TfR) on cell surfaces. – Contains two subunits that each bind one transferrin molecule – Following binding, TfR is internalized by endocytosis accumulating in endosomes – Endosomal pH is lowered to ~5.5, reducing and releasing Fe into cytosol – TfR and transferrin are recycled back to the cell surface |
|
|
PCBP1 & 2 |
PCBP1 & 2 (Poly C binding protein): Cytosolic metallochaperone proteins
– PCBP delivers cytosolic Fe to ferritin – PCBP interacts with DMT1 and ferroportin, thus functions as a gatekeeper for Fe import and export |
|
|
Regulation of Iron absorption |
Fe balance controlled at point of absorption
– Absorption is closely tied to the level of the body’s Fe stores – Absorption is normally low.....~10% with normal Fe status – Absorption is increased (~35%) during Fe deficiency |
|
|
Factors that enhance iron absorption |
Acids, such as ascorbic acid (Vit C) and citric acid → Reducing agents: reduce ferric iron (Fe3+) to the more bioavailable form of ferrous iron (Fe2+) Dietary proteins, such as meats, poultry & fish → Amino acids may improve solubility & promote absorption Amino acids, such as histidine, cysteine, methionine Enhanced erythropoiesis due to hypoxia, hemorrhage, hemolysis, androgens, cobalt, and low Fe status |
|
|
Factors that inhibit iron absorption |
Chelators Polyphenols can reduce Fe absorption by > 60% Phytates and oxalates bind Fe (and other minerals) forming insoluble complexes – EDTA (preservative) – Calcium and phosphorus can inhibit Fe absorption by forming a Fe:Ca:PO4 complex (300 – 600 mg of Ca given with 18 mg of Fe decreased Fe absorption by ~70%) |
|
|
Endogenous factors |
Infection/inflammation, Lack of stomach acid, High Fe status |
|
|
Competitors |
– Zinc, manganese & nickel compete for absorption via DMT1, so large intakes of one mineral can reduce the absorption of the other |
|
|
Regulation of Iron Homeostasis |
Despite environmental abundance, poorly absorbed (likely protective), thus highly conserved once absorbed.
No regulated excretory pathway for iron
Basal or obligatory iron losses include sloughing of dermal cells, sweat, urine, fecal and any type of blood loss including menstruation, blood donation, injury, disease
Cellular and systemic Fe homeostasis should be tightly regulated! |
|
|
Iron as a nutrient |
Iron is essential for numerous heme & nonheme proteins, but can be toxic to cells if Fe levels are too high - Pro-oxidant- formation of free radicals - The most abundant trace mineral in our body & the most abundant mineral on Earth One of the best studied metals in nutrition and healthRole in oxygen and energy metabolism |
|
|
Hemoglobin (Hb) |
- Protein in red blood cells that is responsible for delivery of oxygen to the tissues. - Synthesized in RBCs - 2/3 of total body Fe is located in our RBCs - Allows oxygen transport from the lungs to tissues
|
|
|
Myoglobin
|
Short-term storage of oxygen in muscle
– Supply oxygen to the demand of working muscles |
|
|
Body iron
|
The average adult human contains ~3-4 g iron Erythrocyte hemoglobin (~2-3 g iron) Other iron-rich tissues: liver and spleen |
|
|
Ferrous Iron
|
Fe2+
|
|
|
Ferric Iron
|
Fe3+
|
|
|
Regulation of Iron Status at the Cellular Level |
A major mechanism regulating Fe status at the cellular levels Is post -transcriptional regulation of transferrin receptor, ferritin, and other key factors - Uptake of Fe into cells is proportional to levels of transferrin receptor - Excess Fe must be stored in ferritin to prevent oxidative damage - Transcripts of transferrin receptor and ferritin contain: Iron-responsive elements (IREs), stem-loop RNA structures that control stability and translation of mRNAs - IREs are bound by iron regulatory proteins (IRP1 and IRP2) - Regulate expression of many important factors in iron transport, utilization, and storage in a coordinated way |
|
|
Low Fe concentration in the cell |
- Transferrin Receptor is needed, but Ferritin is not - IRP exists as a 3Fe-4S cluster - IRP binds to the ferritin mRNA IRE (5’ UTR) which decreases translation/synthesis of ferritin - IRP binds to the TfR mRNA (3’ UTR) this stabilizes the mRNA leading to increased translation and synthesis of TfR (-) Ferritin, Ferroportin (+) DMT1, Transferrin receptor |
|
|
High Fe concentration in the cell |
- Ferritin is needed, but TfR is not - IRP exists as 4Fe-4S Cluster - Reduced binding affinity for IRE - The 5’ UTR block on Ft synthesis is removed & Ft levels rise - Concurrently, IRP can no longer bind to the 3’ UTR of TfR and TfR mRNA is rapidly degrade (+) Ferritin, Ferroportin (-) DMT1, Transferrin receptor |
|
|
IREs
|
Iron-responsive elements are stem-loop RNA structures that control stability and translation of mRNAs
|
|
|
IRPs
|
Iron regulatory proteins bind to IREs and regulate expression of many important factors in iron transport, utilization, and storage in a coordinated way
|
|
|
Systemic regulation of iron homeostasis
|
Hepcidin regulates cellular iron by binding ferroportin and inducing its internalization
|
|
|
Hepcidin
|
25 amino-acid peptide hormone
– Released during iron-loading, infection, or inflammation – Synthesized by hepatocytes Directly interacts with ferroportin (Fpn) in enterocytes, macrophages, and hepatocytes Fpn internalization and lysosomal degradation decrease Fe transfer to blood |
|
|
Molecular mechanisms of hepcidin regulation
|
1) BMP/HJV Complex: Model of hepcidin regulation by iron stores
in the liver 2) HFE/TfR2 Complex: Model of hepcidin regulation by plasma Tf “Extracellular signal” = degree of saturation of Tf 3) Inflammation signal: Pathological regulator of hepcidin production |
|
|
Acute-phase response |
Infection/trauma/burns
Human body initiates an inflammatory response Cytokines such as interleukin-6 (IL-6) stimulate hepcidin synthesis in hepatocytes Reduced export of Fe into plasma Results in defective Fe recycling from macrophages Decreased Fe availability for erythropoiesis Cytokines such as IL-1β & TNF-α reduce erythropoiesis by inhibiting erythropoietin (EPO) release Inflammatory marker, C-reactive protein (CRP): used to assess level of inflammation – will be elevated |
|
|
Anemia of Chronic Disease (ACD) |
Chronic Inflammation
Chronic inflammatory disorders, such as cancer, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, leukemia, chronic infection,,,,,,, Inflammation leads to cytokine production Stimulates hepcidin synthesis Reduces iron export Serum iron levels decrease Anemia develops because dietary Fe absorption and Fe mobilization from body stores are inhibited by inflammation-induced hepcidin up-regulation “Anemia of inflammation” |
|
|
Iron function in body - Electron transport and energy metabolism |
Cytochromes and mitochondrial electron transport chain – Cytochromes: heme-containing enzymes involved in mitochondrial electron transport chain (cytochrome b and c) required for cellular energy production – Nonheme iron-containing proteins like NADH dehydrogenase & succinate dehydrogenase are also critical to energy metabolism |
|
|
Iron function in body - Antioxidant |
Catalase
- Heme-containing enzyme - Converts hydrogen peroxide to water and molecular oxygen - Protect cells against the accumulation of hydrogen peroxide, a potentially damaging ROS |
|
|
Iron turnover |
Dietary Fe is important for maintaining long-term Fe status Daily needs are met by efficient conservation and constant recycling of body Fe Most Fe entering plasma has come from sites of hemoglobin destruction and sites of ferritin degradation Heme degradation contributes ~20 – 25 mg of Fe/d Hemoglobin is degraded by phagocytes of the reticuloendothelial system (liver, spleen, bone marrow) RBCs live for ~120 d before degradation – Iron recycling is very efficient ~35 mg being recycled daily |
|
|
Iron excretion |
Daily losses by adult males ~0.9 – 1.0 mg/d Daily losses by post-menopausal women ~0.7 – 0.9 mg/d Losses occur from three main sites: – Gastrointestinal tract (0.6 mg/d) – Skin (0.2 – 0.3 mg/d) – Kidney (~0.08 mg/d) Daily losses by pre-menopausal women ~1.3 – 1.4 mg/d |
|
|
Iron deficiency |
Most common nutrient deficiency in the US & world Estimated to affect 2 – 5 billion people Iron deficiency anemia ~ 39% of children < 5 years of age ~ 48% of 5-to-14 year-old children ~ 42% of women in developing countries Primary causes include: – Low intake of bioavailable Fe – High Fe requirement – Excess blood loss (trauma) – Pathological infections (intestinal or urinary blood loss) Iron deficiency can occur “with or without anemia” |
|
|
Levels of Iron deficiency from least to most severe |
Storage iron depletion Iron stores are depleted, but the functional iron supply is not limited Early functional iron deficiency Before the development of anemia, the supply of functional iron to tissues, including bone marrow, is inadequate such as to impair erythropoiesis Iron-deficiency anemia Iron-deficiency anemia occurs when there is inadequate iron to support normal red blood cell formation |
|
|
Symptoms of Iron deficiency without anemia |
1) Impaired cognitive function Irreversible impairment of learning and cognition can occur with iron deficiency in children 2) Diminished work capacity Oxidative energy production 3) Inability to regulate body temperature Thyroid peroxidase activity (heme-dependent enzyme) for thyroid hormone synthesis 4) Impaired immune function Myeloperoxidase activity (generating free radical response to infection) & changes in lymphocyte and neutrophil function |
|
|
Symptoms of Iron deficiency anemia |
Fe deficiency anemia (microcytic, hypochromic):
– Fatigue – Pica (eating of non-food stuff) – Pallor of the conjunctiva and skin – Nails that break easy and spoon-shaped nails |
|
|
Inherited Iron Overload Diseases |
Hereditary Hemochromatosis – Genetic disorder of iron metabolism – Most common Mendelian inherited trait of Northern Europeans – Fe is progressively deposited in liver, heart & pancreas causing extensive organ damage and ultimately failure Symptoms – Fatigue, joint pain, abnormal pigmentation of skin, organ damage Treatment – Iron depletion therapies including phlebotomy and chelation |
|
|
Types of hereditary hemochromatosis |
1. HFE-related hemochromatosis - Autosomal recessive mutation of HFE gene - Slow progressive Fe accumulation in organs- 4th-5th decade of life 2. Juvenile hemochromatosis - Autosomal recessive mutations in the Hemojuvelin (HJV) gene or hepcidin (HAMP) gene - early onset usually before age 30 3. Transferrin receptor 2-associated hemochromatosis - Autosomal recessive mutation of TfR gene 4. Ferroportin disease - Autosomal dominant mutation of ferroportin gene |
|
|
HFE-related hemochromatosis |
Two mutations (C282Y & H63D) in the HFE gene account for ~90% hemochromatosis in the US HFE gene plays a role in regulating intestinal absorption of dietary iron and with sensing the body’s iron stores In US, approximately 1 in 220 Caucasians are homozygotes for the C282Y mutation – Non-Hispanic whites-heterozygotes 9.5% – Non-Hispanic blacks-heterozygotes 2.3% – Mexican Americans-heterozygotes 2.8% |
|
|
Neurodegeneration with Brain Iron Accumulation |
A group of genetic neurological disorders characterized by abnormal accumulation of iron in the brain and progressive degeneration of the nervous system. Symptoms Movement problems, Dementia, difficulty speaking, difficulty swallowing, muscle problems, seizures, tremor, vision loss, weakness |
|
|
Factors that inhibit calcium absorption |
Oxalic acid: a common compound in plants such as green leafy vegetables (spinach, beet greens), rhubarb, parsley, carrots, cocoa, sweet potatoes Phytates: unrefined cereals, legumes, nuts & seeds |
|
|
Calcium interactions with other nutrients
|
Protein:
Protein intake can contribute to urinary calcium excretion appears to be offset by increased calcium absorption Sodium: High sodium intake results in increased renal calcium excretion – a concern if calcium intake is low Iron: Calcium content of a glass of milk (~ 300 mg) can reduce nonheme absorption by half. Interaction generally not associated with diminished iron status long term with complex meals that contain iron absorption enhancers. |
|
|
Transcellular Absorption of Calcium
|
Facilitated diffusion - limited capacity (saturable)
Highest absorption efficiency in duodenum – to a lesser extent in the jejunum, absent from the ileum Vitamin D plays a significant role Primary absorption mechanism for low Ca2+ intake |
|
|
Paracellular Absorption of Calcium |
Non-saturable diffusion - linear relationship between intestinal lumen calcium content and absorption Occurs throughout the intestine Primary absorption mechanism for higher Ca2+ intake Calcium movement occurs between enterocytes Dependent on calcium concentration in intestinal lumen Appears to be regulated by the permeability of tight junctions Vitamin D increases production of claudins which appear to promote calcium movement through the intercellular space. |
|
|
Vesicular Calcium Transport Model |
Calcium uptake via endocytosis - shown to accumulate in lysosomes in the enterocyte Calcium extruded from the enterocyte via PMCA1b or exocytosis Based on animal studies, may be an absorptive pathway for calcium |
|
|
Calcium Transport/Distribution |
In plasma, total calcium consists of:
30-55% is protein-bound calcium (bound to albumin) 5-15% is calcium complexed with small anions (sulfate, citrate, bicarbonate) ~50% is ionized or free ions (unbound) |
|
|
Biological Function of Calcium |
Free cytosolic calcium levels extremely low compared to ECF levels Ligand binding to cell surface receptors activates a variety of signaling pathways flux of calcium into cytosol Cytosolic calcium functions as a second messenger & cofactor for proteins regulating cellular processes such as:Contraction of muscle, Release of neurotransmitters, Secretion of endocrine hormones, Cell proliferation |
|
|
Determining Calcium Requirements |
Calcium Balance study of adults (19-50y): Goal of setting calcium requirement for this lifestage is to maintain bone health and neutral calcium balance No evidence (at this time) that providing more calcium benefits bone health Slight bone accretion occurs in young adults, however, calcium requirement for this accretion appears low New DRI for calcium based on Hunt and Johnson (2007) data |
|
|
Determining Tolerable Upper Intake Levels |
IOM evaluated research to assess relationship between nutrient dose and adverse effect (duration and severity). NOAEL: highest intake level at which “the adverse effect” is not observed. LOAEL: lowest intake level in which an adverse effect occurred. UF: uncertainty factors – they account for all the potential uncertainties in the process of establishing UL. |
|
|
Describe the photosynthesis of Vitamin D |
During exposure to sunlight, the high-energy UVB (290-315 nm) penetrates the epidermis and photolyzes provitamin D3 or 7-
dehydrocholesterol (7-DHC) to previtamin D3. Once formed, previtamin D3 undergoes a thermally induced isomerization to vitamin D3 that takes 2-3 days to reach completion. Over 90% of the formation of previtamin D3 occurs in the epidermis. Within the epidermis, highest concentration of 7-DHC found in stratum spinosum & basale layers. |
|
|
Factors That Influence UVB Absorption |
Melanin Sunscreen/clothing/barrier Latitude Time of Day Season |
|
|
Dietary Sources of Vitamin D |
Vitamin D3 = (cholecalciferol) made in the skin, found in animal/fish, egg yolks, supplements Vitamin D2 = (ergocalciferol) fungal, yeast, supplements Vitamin D3 and vitamin D2 appear to have similar bioavailability |
|
|
Dietary Vitamin D Absorption |
Absorptive pathway of vitamin D in the intestine not well understood: – Assumed to be similar to lipids micelle-dependent solubilization and diffusion into enterocyte, incorporated into chylomicrons – A small amount of free vitamin D may enter circulation and bind with vitamin D binding protein |
|
|
Vitamin D Binding Protein (DBP) |
Produced in the liver – transport protein for vitamin D
- Once hydroxylated by the liver, 25(OH)D is primarily bound to DBP - small amount bound to albumin |
DBP vs VDR |
|
Vitamin D Metabolism |
- Vitamin D (from skin and diet) is taken up by the liver - Hepatic hydroxylation of vitamin D produces the main circulating (inactive) form 25(OH)D |
|
|
Vitamin D Metabolism - Activation of Vitamin D |
- 25(OH)D (inactive), the main circulating form is primarily bound to DBP. - 25(OH)D is hydroxylated by renal 1α-hydroxylase (CYP27B1) generating 1,25(OH)2D, the active form. |
|
|
Vitamin D3 |
(cholecalciferol) made in the skin or consumed in diet (animal/fish, supplements)
|
|
|
Vitamin D2 |
(ergocalciferol) fungal, yeast
|
|
|
Megalin |
found on the apical surface of renal tubule cells is a receptor for DBP. Promotes the recycling of vitamin D.
|
|
|
Regulation of renal 1α-hydroxylase (CYP27B1)
|
(+) PTH, hypocalcemia
(-) FGF23, 1,25(OH)2D, hypercalcemia |
|
|
Role of Vitamin D in Calcium Intestinal Absorption
|
Active form of vitamin D binds to its Vitamin D Receptor (VDR) in cell nucleus, complexes with RXR, binds to Vitamin D Receptor Element (VDRE) inducing the synthesis of TRPV6, calbindin, PMCA1b, and NCX1 in the intestine.
|
|
|
Factors that increase renal reabsorption of calcium |
- Parathyroid hormone (PTH) - Vitamin D (active form) - Fibroblast-like growth factor 23 (FGF-23) - Hypocalcemia |
|
|
Role of 1,25(OH)2D in maintaining calcium homeostasis (Intestine) |
Vitamin D helps to maintain calcium homeostasis in the intestine by increasing calcium absorption in the intestine. The active form of vitamin D enters the enterocyte from the blood. 1,25(OH)2D then binds to its Vitamin D receptor (VDR) in the nucleus of the enterocyte and activates calcium transport related genes such as TRPV6, calbindin, PMCA1b, and NCX1. This greatly increases the amount of calcium absorbed in the intestine. |
|
|
Role of 1,25(OH)2D in maintaining calcium homeostasis (Kidney) |
The activation of calcium transport-related genes, such as TRPV5, calbindin, PMCA1b, and NCX1, leads to an increase in renal reabsorption of calcium.
|
|
|
Role of 1,25(OH)2D in maintaining calcium homeostasis (bone) |
- Vitamin D 1,25(OH)2D binds to the vitamin D receptor in the osteoblast - Ligand within the osteoblast (RANKL) is increased - RANKL then binds to RANK, the osteoclast precursor - Binding action triggers the formation of osteoclasts which will then go on to break down old bone tissue. As a result, the bone releases calcium in addition to other minerals. This increases the level of calcium in the extracellular fluid |
|
|
FGF23 role in maintaining calcium homeostasis
|
High levels of the active form of Vitamin D (1,25(OH)2D) will eventually stimulate the production of FGF23 by osteoblasts and osteocytes in the bone.
- FGF23 inhibits parathyroid hormone (PTH) production and secretion. - FGF23 also decreases 1a-hydroxylase. FGF23’s inhibitory action on PTH and 1a-hydroxylase decreases the activation of Vitamin D in the kidney. - This slows the breakdown of bone tissue helping to regulate that process. - Prevents excessive loss of calcium and helps to maintain calcium homeostasis. |
|
|
FGF23 increases calcium reabsorption in the kidney by increasing
|
TRPV5 synthesis
|
|
|
What happens when 1,25(OH)2D binds Vitamin D receptor (VDR) in the nucleus of the enterocyte
|
TRPV6, calbindin, PMCA1b, and NCX1 are increased
|
|
|
TRVP6 |
Intestine
|
|
|
TRVP5 |
Kidney
|
|
|
PCBP |
PCBP1&2(PolyC binding protein): Cytosolic metallochaperone proteins – PCBP delivers cytosolic Fe to ferritin – PCBP interacts with DMT1 and ferroportin, thus functions as a gatekeeper for Fe import and export |
|
|
HCP |
Heme carrier protein |
|
|
HRG |
Heme responsive gene |
|
|
Model of hepcidin regulation by iron storesin the liver |
BMP/HJV Complex |
|
|
Model of hepcidin regulation by plasma Tf “Extracellular signal” = degree of saturation of Tf |
HFE/TfR2 Complex |
|
|
Genomic function of Vitamin D |
– 1,25(OH)2D - VDR complex binds toVDREs (specific DNA promotersequences) – Many genes regulated by vitamin D |
|
|
Nongenomic functions of Vitamin D |
– Rapid response to 1,25(OH)2D – Pathways have been identified in whichvitamin D mediates a rapid response –triggers signaling cascades – Mechanism of action not wellunderstood though appears to be amembrane mediated response |
|
|
Vitamin D insufficiency |
Myopathy Diabetes Neurological diseases Coronary disease Hypertension/arteriosclerosis Autoimmune diseases |
|
|
24 hydroxylase |
Turns active or inactive Vit D into inactive form to be excreted (+) Catabolism of 1,25(OH)2D |
|
|
24 hydroxylase is regulated by |
(+) FGF23, 1,25(OH)2D (-) PTH |
|
|
Intracellular Calcium Signaling |
Free cytosolic Ca levels are much lower than extracellular fluid Cytosolic calcium levels must be maintained at a low level because it functions as a second messenger & cofactor for proteins regulating cellular processes such as: - contraction of muscles (cramps, spasms) - release of neurotransmitters - secretion of endocrine hormones - cell proliferation (cancer) |
|
|
HFE |
hemochromatosis protein |
|
|
HJV |
hemojuvelin (gene) - may be mutated in Juvenile hemochromatosis |
|
|
hemochromatosis |
iron overload |
|
|
BMP |
Bone morphogenetic protein; part of BMP/HJV Complex |
|